| Biological Sciences | Lifetime | 955 | US 515 | 99.88 |
| Biological Sciences | 2021-2025 | 538 | US 120 | 99.42 |
| Clinical Biochemistry | Lifetime | 20 | US 12 | 99.53 |
| Infectious Diseases | Lifetime | 106 | US 55 | 99.68 |
| Molecular Medicine | Lifetime | 17 | US 4 | 99.67 |
| Applied Microbiology and Biotechnology | Lifetime | 9 | US 2 | 99.40 |
| Clinical Pharmacology | Lifetime | 177 | US 79 | 99.28 |
| Epidemiology | Lifetime | 586 | US 296 | 99.26 |
| Endocrinology | Lifetime | 72 | US 38 | 98.92 |
| Veterinary Science and Animal Health | Lifetime | 727 | US 261 | 86.19 |
| Microbiology | Lifetime | 656 | US 281 | 79.39 |
| Molecular Medicine | 2021-2025 | 16 | US 3 | 98.79 |
| Applied Microbiology and Biotechnology | 2021-2025 | 6 | US 1 | 98.38 |
| Clinical Pharmacology | 2021-2025 | 96 | US 32 | 96.69 |
| Clinical Biochemistry | 2021-2025 | 29 | US 7 | 92.14 |
| Endocrinology | 2021-2025 | 40 | US 12 | 91.68 |
| Infectious Diseases | 2021-2025 | 518 | US 199 | 88.98 |
| Antibiotic Resistance in Bacteria | Lifetime | 28 | US 8 | 99.87 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 21 | US 10 | 99.83 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 15 | US 8 | 99.82 |
| Antibiotic Use and Resistance | Lifetime | 14 | US 6 | 99.84 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 25 | US 17 | 99.80 |
| Pneumonia and Respiratory Infections | Lifetime | 94 | US 46 | 99.58 |
| Infections and bacterial resistance | Lifetime | 9 | US 3 | 99.56 |
| Streptococcal Infections and Treatments | Lifetime | 99 | US 58 | 99.20 |
| Bacterial biofilms and quorum sensing | Lifetime | 134 | US 48 | 99.09 |
| Enterobacteriaceae and Cronobacter Research | Lifetime | 40 | US 13 | 98.52 |
| Urinary Tract Infections Management | Lifetime | 152 | US 79 | 98.74 |
| Nosocomial Infections in ICU | Lifetime | 104 | US 37 | 98.96 |
| Infective Endocarditis Diagnosis and Management | Lifetime | 320 | US 156 | 98.70 |
| Pharmaceutical and Antibiotic Environmental Impacts | Lifetime | 268 | US 40 | 98.70 |
| Veterinary medicine and infectious diseases | Lifetime | 192 | US 53 | 96.48 |
| Vibrio bacteria research studies | Lifetime | 571 | US 217 | 96.13 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 874 | US 362 | 96.04 |
| Humic Substances and Bio-Organic Studies | Lifetime | 480 | US 74 | 53.47 |
| Antibiotic Use and Resistance | 2021-2025 | 19 | US 3 | 99.08 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 39 | US 8 | 99.26 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 31 | US 8 | 98.80 |
| Antimicrobial Resistance in Staphylococcus | 2021-2025 | 44 | US 13 | 97.34 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 47 | US 12 | 97.72 |
| Pneumonia and Respiratory Infections | 2021-2025 | 797 | US 211 | 88.04 |
| Urinary Tract Infections Management | 2021-2025 | 398 | US 125 | 86.00 |
| Infections and bacterial resistance | 2021-2025 | 50 | US 11 | 84.77 |
| Nosocomial Infections in ICU | 2021-2025 | 336 | US 66 | 83.17 |
| Plant Pathogenic Bacteria Studies | 2021-2025 | 767 | US 117 | 77.54 |
| Vibrio bacteria research studies | 2021-2025 | 832 | US 142 | 76.87 |
| Enterobacteriaceae and Cronobacter Research | 2021-2025 | 355 | US 33 | 58.84 |
